NSC 23766

For research use only. Not for use in humans.

目录号:S8031

NSC 23766 Chemical Structure

CAS No. 1177865-17-6

NSC 23766是一种Rac GTPase抑制剂,通过鸟嘌呤核苷酸因子(GEFs)靶向作用于Rac 活化,无细胞试验中IC50为~50 μM;但是不会抑制密切相关的靶点,Cdc42或RhoA。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1139.63 现货
RMB 901.16 现货
RMB 3849.78 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的NSC 23766发表文献70篇:

产品安全说明书

Rho抑制剂选择性比较

生物活性

产品描述 NSC 23766是一种Rac GTPase抑制剂,通过鸟嘌呤核苷酸因子(GEFs)靶向作用于Rac 活化,无细胞试验中IC50为~50 μM;但是不会抑制密切相关的靶点,Cdc42或RhoA。
靶点
Rac GTPase [1]
(Cell-free assay)
50 μM
体外研究

NSC23766被认为可以融入Rac1的表面沟槽,Rac1对GEF规格至关重要。NSC23766通过Rac特异性的GEF Trio或 Tiam1,有效地抑制Rac1结合和激活,这种作用具有剂量依赖性,通过其各自的GEFs,不干扰紧密相关的Cdc42或RhoA结合或激活。NSC23766有效调节细胞骨架中的Rac GTPase功能,和许多细胞功能,包括细胞周期,细胞生长,粘附,迁移和基因转录。NSC 23766 (50 μM)作用于NIH 3T3细胞,有效抑制血清或血小板衍生的生长因子诱导的Rac1激活和伪足形成,不影响内源性Cdc42或RhoA活性。NSC23766降低Trio 或 Tiam1而不是Vav, Lbc, Intersectin, 和组成型激活的Rac1突变型刺激的NIH 3T3细胞生长,也抑制Trio, Tiam1,或Ras诱导的细胞转化。NSC23766 抑制PC-3细胞增殖和锚定非依赖性生长,这种作用存在剂量依赖性。25 μM NSC23766抑制85%PC-3细胞侵袭穿过基底膜。[1]50 μM NSC 23766作用于人体血小板,抑制凝血酶诱导的Rac1和Rac2激活,以及血小板聚集。[2]NSC23766作用于swAPP-HEK293细胞,抑制Aβ40 和 Aβ42产生,不影响Notch 和 sAPPα。NSC23766 抑制细胞中γ-分泌酶活性,但是不是作为直接的γ-分泌酶抑制剂。NSC23766降低分泌的和细胞内的 Aβ40水平,IC50为48.94 μM,这种作用具有剂量依赖性。50 μM NSC 23766抑制57.97% Aβ42 释放。[3] NSC23766调节内皮NO合酶表达和内皮功能。100μM NSC23766抑制eNOS启动子活性,牛主动脉内皮细胞中抑制60%,bEND.3细胞中抑制30%至35%。NSC23766抑制Rac1,破坏eNOS mRNA稳定性,半衰期缩短到17小时。NSC23766 抑制ACh诱导的野生型小鼠主动脉环放松,这种作用存在剂量依赖性。[4]NSC23766抑制细胞生长,且诱导细胞凋亡。NSC23766降低MDA-MB-468和MDA-MB-231细胞活力,这种作用存在剂量依赖性, IC50 为~10 μM,与雌激素受体(ER),孕酮受体(PR),Her2,和p53基因突变状态无关。NSC23766对MCF12A正常乳腺上皮细胞的存活几乎没有影响。NSC 23766处理MDA-MB-231细胞24小时后,G1期细胞增长41%至65%,S和G2-M期随之减少。100 μM NSC23766诱导MDA-MB-468细胞凋亡增长6倍。NSC23766作用于乳腺癌细胞,抑制细胞周期停滞或凋亡,通过下调cyclin D1, survivin, X-连锁蛋白凋亡抑制剂(XIAP)而调节。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
RA4 NUX0cGdITnWwY4Tpc44hSXO|YYm= NX3hdJhrPTBizszN M1PuRVI1KGh? MkfhbY5pcWKrdIOgUYF1emmpZXygbY53[XOrb36= M4m5RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkKyN|A5Lz5zN{[yNlMxQDxxYU6=
RA3 MWrGeY5kfGmxbjDBd5NigQ>? MVe1NEDPxE1? M1P4RlI1KGh? M3L0TIlvcGmkaYTzJG1ifHKrZ3XsJIlvfmG|aX;u NHSzcHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[yNlMxQCd-MUe2NlI{ODh:L3G+
RA2 MXTGeY5kfGmxbjDBd5NigQ>? MYe1NEDPxE1? NUm4OpVjOjRiaB?= NEHQU41qdmirYnn0d{BO[XS{aXflcEBqdn[jc3nvci=> NYn0SoI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2NlI{ODhpPkG3OlIzOzB6PD;hQi=>
RA1 MUPGeY5kfGmxbjDBd5NigQ>? MWW1NEDPxE1? MUOyOEBp M3nvVYlvcGmkaYTzJG1ifHKrZ3XsJIlvfmG|aX;u Ml\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4MkKzNFgoRjF5NkKyN|A5RC:jPh?=
RA-FLS (RA2)  NEL5PXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKyOU82OCEQvF2= MXqxMVkh\A>? M1fa[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ NVza[IZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2NlI{ODhpPkG3OlIzOzB6PD;hQi=>
IEC-6  MnGwSpVv[3Srb36gRZN{[Xl? M1fCe|EzOCEEtV2= MkPhOE83NzhiaB?= M1TSOJBz\X[nboTzJJRp\SCrbnPy[YF{\WRiYXP0bZZifGmxbjDv[kBHSUtiYYSgOkBidmRiODDo NIO2[YE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES0PFQ3OSd-MkC0OFg1PjF:L3G+
MDA-MB-231  NGDmfphHfW6ldHnvckBCe3OjeR?= NHf4XZQ2OC9zMECg{txO NUfwVmFqPDhiaB?= NFXKU5BqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSg[IVkemWjc3WgbY4heGixc4Doc5J6dGG2aX;uJI9nKHB4NTDzeYJ2dmm2 NF\R[mU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWxOVk1OCd-MkC1NVU6PDB:L3G+
MDA-MB-468 M{Hl[2Z2dmO2aX;uJGF{e2G7 NYX2VVR4PTBxMUCwJO69VQ>? NYWxfHBVPDhiaB?= M{C0fYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDk[YNz\WG|ZTDpckBxcG:|cHjvdplt[XSrb36gc4YheDZ3IIP1ZpVvcXR? Ml;MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3MUW5OFAoRjJyNUG1PVQxRC:jPh?=
MDA-MB-231  M1PURmZ2dmO2aX;uJGF{e2G7 NVnFSmZxPTBxMUCwJO69VQ>? MnTONlQhcA>? MY\pcoNz\WG|ZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGpPUyCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M3La[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUG1PVQxLz5{MEWxOVk1ODxxYU6=
MDA-MB-468 M4T1R2Z2dmO2aX;uJGF{e2G7 Mk[xOVAwOTByIN88US=> M1T0e|I1KGh? NGfuXY1qdmO{ZXHz[ZMheGixc4Doc5J6dGG2aX;uJI9nKEqQSzDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NFLPN289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWxOVk1OCd-MkC1NVU6PDB:L3G+
MDA-MB-468 MYDGeY5kfGmxbjDBd5NigQ>? Mnv5NVAxKM7:TR?= Mlu2NlQhcA>? MoLQbY5pcWKrdIRCpINie3Cjc3WtN{Bi[3SrdnH0bY9vyqB? NIDyZ409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWxOVk1OCd-MkC1NVU6PDB:L3G+
MDA-MB-468 MlmwRZBweHSxc3nzJGF{e2G7 MWi1NE8yODBizszN MonQNlQhcA>? NEX2R2FqdmS3Y3XzJIFxd3C2b4Ppdy=> M1;Z[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUG1PVQxLz5{MEWxOVk1ODxxYU6=
T47D NEO4[nNHfW6ldHnvckBCe3OjeR?= M1nrR|ExOCEQvF2= NFnxW4c1QCCq MmTnbY5kemWjc3XzJJRp\SClZXzsJI52dWKncjDpckBIOcLicHjhd4Uh[W6mIHTlZ5Jm[XOnczD0bIUh[2WubDDueY1j\XJiaX6gV{BidmRiR{KtUUBxcGG|ZYRCpC=> MmrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3MUW5OFAoRjJyNUG1PVQxRC:jPh?=
MCF7 MlrKSpVv[3Srb36gRZN{[Xl? NFG3U5YyODBizszN NX3QWHFwPDhiaB?= NHHrd4lqdmO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJIlvKEdzwrDwbIF{\SCjbnSg[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDpckBUKGGwZDDHNk1OKHCqYYPld:Kh MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODVzNUm0NEc,OjB3MUW5OFA9N2F-
MDA-MB-231  MU\GeY5kfGmxbjDBd5NigQ>? NXnmRWFJOTByIN88US=> MnvIOFghcA>? M3\iRolv[3KnYYPld{B1cGViY3XscEBvfW2kZYKgbY4hTzIEoIDoZZNmKGGwZDDk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IHnuJHMh[W6mIFeyMW0heGijc3XzxsA> M1OwTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUG1PVQxLz5{MEWxOVk1ODxxYU6=
MDA-MB-231 MVPGeY5kfGmxbjDBd5NigQ>? MX:wMVExOCEQvF2= Mlu5NlQhcA>? MXHz[Yxm[3SrdnXsfUBqdmirYnn0d{BT[WNzIHHjeIl3[XSrb36ge4l1cG:3dDDpcpRmem[ncnnu[{B4cXSqIITo[UBi[3Srdnn0fUBw\iC2aHWgZ4xwe2WueTDy[YxifGWmIIPtZYxtKEeWUHHz[UBE\GN2Mh?= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODVzNUm0NEc,OjB3MUW5OFA9N2F-
MDA-MB-231 MkP0R5l1d3SxeHnjbZR6KEG|c3H5 M3TPZlAuOTByIN88US=> MkHjOFghcA>? M{DIUIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= Mle5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3MUW5OFAoRjJyNUG1PVQxRC:jPh?=
MDA-MB-468 MVvDfZRwfG:6aXPpeJkhSXO|YYm= Mlj4NE0yODBizszN MUe0PEBp NUXaZlRW\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M{PjeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUG1PVQxLz5{MEWxOVk1ODxxYU6=
T47D MkLoR5l1d3SxeHnjbZR6KEG|c3H5 M1HkcVAuOTByIN88US=> NWHkdFNlPDhiaB?= M1PsUYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODVzNUm0NEc,OjB3MUW5OFA9N2F-
MCF7 Ml36R5l1d3SxeHnjbZR6KEG|c3H5 MmriNE0yODBizszN MVm0PEBp NVzCNmV6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NF7sfY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWxOVk1OCd-MkC1NVU6PDB:L3G+
SKBR3-pMKO.1 NIW2XopHfW6ldHnvckBCe3OjeR?= MlXHOVAh|ryP NF\E[HEzPCCq NWfuOHdVcW6qaXLpeJMhWmGlMTDhZ5RqfmG2aX;u MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2M{iyOUc,OjF7NEO4NlU9N2F-
SKBR3 Ml64SpVv[3Srb36gRZN{[Xl? MnTmOVAh|ryP MV[yOEBp NHfwNVBqdmirYnn0d{BT[WNzIHHjeIl3[XSrb36= M2TLd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUSzPFI2Lz5{MUm0N|gzPTxxYU6=
NCI-H1703 NXrjPYdzTnWwY4Tpc44hSXO|YYm= MlLiNE02ODBizszN NX3udoNUOjRiaB?= NEL1bWllcW2rbnnzbIV{KGKjc3HsJG5HNc78QjDhZ5Rqfmm2eTDkc5NmKGSncHXu[IVvfGy7wrC= NXS2UYpzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFkyPjBpPkKyOVQ6OTZyPD;hQi=>
NCI-H1703 Ml61SpVv[3Srb36gRZN{[Xl? NHzDRWIyODBizsznM41t NF7UXGQzPCCq M2HtXJNtd3e|IIDyc4dz\XO|aX;uJJRpem:3Z3igeIhmKEdzwrDwbIF{\SCxZjD0bIUh[2WubDDjfYNt\Q>? NYPIUlM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFkyPjBpPkKyOVQ6OTZyPD;hQi=>
NCI-H1703 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKwMVUxOCEQvF2= NGfE[3IzPCCq MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NXHXclZ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFkyPjBpPkKyOVQ6OTZyPD;hQi=>
T98MG NH3QR3dHfW6ldHnvckBCe3OjeR?= NHjON|g2OCCvTR?= MXOyOEBp NGHr[2hFVVOR NHLEeVZmdmijbnPld{B1cGViYX70bY1q\3KjdH;yfUBm\m[nY4Sgc4Yh\XKub4Tpcolj NFXJfnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{izNlEzOCd-MkO4N|IyOjB:L3G+
A172MG M33BOGZ2dmO2aX;uJGF{e2G7 MV61NEBuVQ>? NH\NOnkzPCCq NEPPSWVFVVOR MWLlcohidmOnczD0bIUh[W62aX3p[5JifG:{eTDl[oZm[3Rib3[g[ZJtd3Srbnni MmTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6M{KxNlAoRjJ|OEOyNVIxRC:jPh?=
U87MG M1WzUWZ2dmO2aX;uJGF{e2G7 MmPNOVAhdU1? NF3ZO48zPCCq M{LkNmROW09? NY[0TYJ7\W6qYX7j[ZMhfGinIHHueIlucWe{YYTvdpkh\W[oZXP0JI9nKGW{bH;0bY5q[g>? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh|MkGyNEc,OjN6M{KxNlA9N2F-
PC40 MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmPJOVAhdU1? MX6xOFQhcA>? MVTEUXNQ Mmq5[ZhpcWKrdIOgd5lv\XKpaYP0bYMh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0d{Bkd22kaX7l[EB1emWjdH3lcpQhf2m2aDDldoxwfGmwaXNCpC=> MkHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6M{KxNlAoRjJ|OEOyNVIxRC:jPh?=
PC38 MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYC1NEBuVQ>? MVmxOFQhcA>? NES5NnVFVVOR MlvI[ZhpcWKrdIOgd5lv\XKpaYP0bYMh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0d{Bkd22kaX7l[EB1emWjdH3lcpQhf2m2aDDldoxwfGmwaXNCpC=> MoWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6M{KxNlAoRjJ|OEOyNVIxRC:jPh?=
T98MG NFvOUJNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NIT5flg2OCCvTR?= M4C4WVE1PCCq M3P6fWROW09? MUTlfIhq[mm2czDzfY5memerc4TpZ{BidnSrcILvcIln\XKjdHn2[UBm\m[nY4TzJINwdWKrbnXkJJRz\WG2bXXueEB4cXSqIHXycI91cW6rYtMg MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh|MkGyNEc,OjN6M{KxNlA9N2F-
A172MG NWOySFJMS2WubDDWbYFjcWyrdImgRZN{[Xl? NGDu[FY2OCCvTR?= MVOxOFQhcA>? Mn;qSG1UVw>? MXrlfIhq[mm2czDzfY5memerc4TpZ{BidnSrcILvcIln\XKjdHn2[UBm\m[nY4TzJINwdWKrbnXkJJRz\WG2bXXueEB4cXSqIHXycI91cW6rYtMg MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh|MkGyNEc,OjN6M{KxNlA9N2F-
U87MG NEixO|BE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmC2OVAhdU1? Mki5NVQ1KGh? MorhSG1UVw>? M4nRboV5cGmkaYTzJJN6dmW{Z3nzeIlkKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeJMh[2:vYnnu[YQhfHKnYYTt[Y51KHerdHig[ZJtd3SrbnnixsA> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh|MkGyNEc,OjN6M{KxNlA9N2F-
Ki-67+ CLL NFywUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zmO|UxKML3TR?= NVWzOo55PSCm M4X4UIRm[3KnYYPld{B1cGViboXtZoVzKG:oIFvpMVY4M8LiQ1zMJINmdGy| NWfMWZR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NFEzOTdpPkK0OVAyOjF5PD;hQi=>
NIH3T3  NVHrVGNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXkXGtWOTByIN88US=> NY\PcHN2OjUEoHi= MonCbIF{KG6xIIPp[45q\mmlYX70JIlueGGldDDvckBk\WyuII\pZYJqdGm2eR?= Mo\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyM{ewOlAoRjJ3MEO3NFYxRC:jPh?=
U2-OS MlX6SpVv[3Srb36gRZN{[Xl? MlXCNVAxKM7:TR?= MWKyOEBp MX;EUXNQ M4[5fIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hfGinIFexJJBp[XOnwrC= Mm\JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzNlcoRjJ3MUC5N|I4RC:jPh?=
SW480  NHP1cldHfW6ldHnvckBCe3OjeR?= NVj3bHhTOTByIN88US=> Mn35NlQhcA>? MkmwSG1UVw>? NETFOpVqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKHSqZTDHNUBxcGG|ZdMg MlraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzNlcoRjJ3MUC5N|I4RC:jPh?=
A431 MYTGeY5kfGmxbjDBd5NigQ>? NVnFXFMyOTByIN88US=> MnO4NlQhcA>? Mn7CSG1UVw>? NFLVfVZqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKHSqZTDHNUBxcGG|ZdMg MkfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzNlcoRjJ3MUC5N|I4RC:jPh?=
U2-OS NH;uOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHkUWYyODBizszN NIfYXJEzPC92OD:3NkBp MYnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> Mle3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzNlcoRjJ3MUC5N|I4RC:jPh?=
SW480  NGXWbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKxNFAh|ryP NX30OHpzOjRxNEivO|IhcA>? NYO1dFJ[cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? NGTTeIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVMzPyd-MkWxNFk{Ojd:L3G+
A431 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrKdXlSOTByIN88US=> M{nYcFI1NzR6L{eyJIg> NGjhO2lqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyOUOyO{c,OjVzMEmzNlc9N2F-
RBMECs M2PySGZ2dmO2aX;uJGF{e2G7 M4rWOFExOCEQvF5CpC=> MVOzNOKhdWmw Ml6xZoxw[2unczC2Ro57NWODTWCtcYVlcWG2ZXSgZYN1cX[jdHnvckBw\iCUYXOxJIlvKEWPQWCtTWkufHKnYYTl[EBTSk2HQ4O= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3OECzPUc,OjZ|NUiwN|k9N2F-
human aortic smooth muscle cells MoroSpVv[3Srb36gRZN{[Xl? MWW1NEB2VQ>? NX[zTGduUW6qaXLpeIlwdiCxZjDSZYMyKGKrbnTpcochfG9iUHHrNUBqdiCqdX3hckBid3K2aXOgd41wd3SqIH31d4Nt\SClZXzsd{BifCB3MDD1UUBjgSCVRGOtVGFITSCkYYPl[EBkcGWvaXz1cYlv\XOlZX7j[S=> NUnC[XdRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1NlcxOzJpPkG5OVI4ODN{PD;hQi=>
human aortic smooth muscle cells MX;GeY5kfGmxbjDBd5NigQ>? NUXXZmVOOTByIN88US=> NYXnRVRJUW6qaXLpeIlwdiCxZjDSZYMyKGKrbnTpcochfG9iUHHrNUBqdiCqdX3hckBid3K2aXOgd41wd3SqIH31d4Nt\SClZXzsd{BifCBzMECgeW0h[nliU1TTMXBCT0ViYnHz[YQh[2inbXnseY1qdmW|Y3XuZ4U> NX25VHZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1NlcxOzJpPkG5OVI4ODN{PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pCREB / CREB; 

PubMed: 25319697     


Rac1 inhibitor NSC23766 decreases CREB phosphorylation at serine 133 (pCREB) in cortical neurons. Left, Temporal profiles of NSC23766 (100 μm) on basal pCREB levels. Right, Dose–response effects of NSC23766 (30 min) application on pCREB. 

OCT4 / SOX2 / Nanog ; 

PubMed: 31338333     


Down-regulation of Rac1-GTP treated with NSC23766 decreased expression of Nanog, Sox2, and Oct4 levels in TUFT1—MDA-MB-231 and TUFT1—HCC1937 cells (n = 3). 

active Rac1 / Rac1 ; 

PubMed: 31338333     


Western blot showed effect of Rac1 inhibitor NSC23766 on Rac1-GTP in MDA-MB-231 cells (n = 3). 

25319697 31338333
Immunofluorescence
IP3K-A / F-actin; 

PubMed: 19890013     


Rac1-specific inhibitor NSC23766 gradually blocked the IP3K-A expression-induced formation of filopodia in HeLa cells. Following transfection of GFP-IP3K-A, HeLa cells were incubated for 24 hrs in medium containing the Rac1 inhibitor. Treatment with 40 µM䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙

BART / Rac1; 

PubMed: 22745590     


S2-013 cells were pretreated with or without the Rac1 inhibitor (NSC23766) and were immunocytochemically stained using anti-BART (green) and anti-Rac1 (red) antibodies. Arrows indicate colocalized BART and Rac1 in lamellipodial-like protrusions; blue, DAP䲧疝Ỵ疞㧀疜膉痘 

19890013 22745590
体内研究 NSC23766诱导造血干细胞/前体细胞动员。NSC23766按2.5 mg/kg剂量腹腔注射到驱动不良的C57Bl/6小鼠品系,注射6小时后,导致循环中的造血干细胞/前体细胞增强2倍。[2]NSC23766处理小鼠,减轻脂多糖诱导的急性肺损伤。NSC23766按1或3 mg/kg剂量处理,不仅降低炎性细胞浸润和MPO活性,也抑制促炎介质,和肿瘤坏死因子-α,白细胞介素-1β,mRNA表达。NSC23766也降低Evans Blue和清蛋白在LPS处理的肺部积累。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

Rho GTPase活性测定:

10-cm培养皿中的对数生长期细胞生长在0.5%血清培养基中饥饿处理24小时,然后溶解在含20 mM Tris HCl (pH 7.6), 100 mM NaCl, 10 mM MgCl2, 1% Nonidet P-40, 10% 甘油, 和1×蛋白酶抑制剂混合物的Buffer中。澄清裂解液,蛋白浓度归一化,通过效应结构域下拉检测测量裂解液中与GTP结合的Rac1。His6-PAK1 PBD拉下实验中,E. coli纯化的Ni2+-琼脂糖固定的His6-PAK1 PBD域与细胞裂解液温育30分钟。使用anti-Rac1单克隆抗体,通过免疫印迹,在洗涤缓冲液中洗涤两次Ni2+琼脂糖共同沉淀。
细胞实验:[5]
- 合并
  • Cell lines: 人类乳腺癌细胞 MDA-MB-468
  • Concentrations: 0-100 μM
  • Incubation Time: 2 天
  • Method: 细胞按1.5×104个/mL接种在96孔组织培养板中,孔中含200 μL培养基。 接种24小时后, 使用含指定浓度NSC23766的 200 μL新鲜培养基置换原来的培养基。处理末期,每孔加入20 μL MTS 溶液,在37°C下温育2小时。在96孔板酶标仪上读取490 nm处吸光值。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL warmed (188.33 mM)
Water 100 mg/mL warmed (188.33 mM)
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 530.96
化学式

C24H35N7.3HCl

CAS号 1177865-17-6
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Rho Signaling Pathway Map

Tags: 购买NSC 23766 | NSC 23766供应商 | 采购NSC 23766 | NSC 23766价格 | NSC 23766生产 | 订购NSC 23766 | NSC 23766代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID